Last edited 11/2020 and last reviewed 04/2022
Diabetic retinopathy (DR) is a chronic progressive, potentially sight-threatening disease of the retinal microvasculature associated with the prolonged hyperglycaemia and other conditions linked to diabetes mellitus such as hypertension (1).
- DR is the most common eye problem associated with diabetes
- other ocular complications of diabetes may include:
- specific to progression of the ocular disease e.g. - cataract, rubeosis ridis
- non-specific recognised associations of diabetes in the eye e.g. - glaucoma, retinal vein occlusion/optic disc swelling (1)
- it is a microangiopathy affecting the retinal precapillary arterioles, the capillaries and the venules
The risk of developing diabetic retinopathy is greater with longer duration of diabetes
- large longitudinal studies of patients with diabetes in Wisconsin reported that
- retinopathy develops within five years of diagnosis of diabetes in about
- 25% of people with type 1 diabetes
- 40% of people with type 2 diabetes who are taking insulin and 24% of people with type 2 diabetes who are not taking insulin
- the 25 year cumulative rate of progression to
- diabetic retinopathy was 83%
- diabetic macular oedema was 29%
- clinically relevant macular oedema was 17%
- in addition to duration of diabetes, poor glycaemic control and uncontrolled hypertension is also associated with greater risk of DR (when compared to patients with good control of these factors) (2,3)
- control of serum glucose and blood pressure have been shown to be effective in preventing vision loss due to DR
- DR is the leading cause of vision loss in adults aged 20–74 years (4)
A change in the vision in DR has two basic mechanisms:
- retinopathy - diabetes related damage to the whole retina
- maculopathy - specific diabetes related damage to the central fovea (3).
From 1990–2010, diabetic retinopathy (DR) ranked as the fifth most common cause of preventable blindness and fifth most common cause of moderate to severe visual impairment (5)
- in 2010, of an estimated 285 million people worldwide with diabetes, over one-third have signs of DR, and a third of these are afflicted with vision-threatening diabetic retinopathy (VTDR)
- defined as severe non-proliferative DR or proliferative DR (PDR) or the presence of diabetic macular edema (DME) (6)
- PDR is the most common vision-threatening lesion particularly among patients with type 1 diabetes
- DME is responsible for most of the visual loss experienced by patients with diabetes as it remains the major cause of vision loss in the highly prevalent type 2 diabetes
- also is invariably present in patients with type 2 diabetes with PDR (7)
- (1) The Royal College of Ophthalmologists (RCOphth) 2012. Diabetic retinopathy guidelines
- (2) Ockrim Z, Yorston D. Managing diabetic retinopathy. BMJ. 2010;341:c5400.
- (3) Broadbent D. Diabetic retinopathy: Fundamentals for primary care. Diabetes & Primary Care 2013;Vol 15 No 4
- (4) Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124–36.
- (5) Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H, et al.
Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet
Glob Health. 2013;1(6):e339–49.
- (6) Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al.
Global prevalence and major risk factors of diabetic retinopathy. Diabetes
- (7)Tong L, Vernon SA, Kiel W, Sung V, Orr GM. Association of macular involvement with proliferative retinopathy in type 2 diabetes. Diabet Med. 2001;18(5):388–94.